Organogenesis, Inc. to Develop Regenerative Medicine Therapies for
U.S. Military Battlefield Injuries
Consortium Wins Grant to Form New Armed Forces Institute of
Regenerative
Medicine (AFIRM)
CANTON, Mass. and WASHINGTON, April 17 /PRNewswire/ --
Organogenesis, Inc., the world's most successful regenerative
medicine company, announced today that it is part of a consortium --
spearheaded by the Institute for Regenerative Medicine at Wake Forest
University Baptist Medical Center -- which has been awarded $42.5
million over five years by the U.S. Army Institute of Surgical
Research (ISR) to co-lead one of two academic groups that will form
the Armed Forces Institute of Regenerative Medicine (AFIRM).
The collaboration will be headed by the Wake Forest Institute for
Regenerative Medicine, and the McGowan Institute for Regenerative
Medicine at the University of Pittsburgh. A second consortium will be
managed by Rutgers and the Cleveland Clinic.
The two consortiums, working with the ISR, will use the science of
regenerative medicine to develop new treatments for wounded soldiers.
"We are proud that Organogenesis will play a key role in the
development of better treatments of battlefield injuries through the
use of regenerative medicine," said Geoff Mackay, CEO of
Organogenesis. "We believe that our experience as pioneers in the
translation of regenerative medicine technology from visionary
science and laboratory research, to therapies used to benefit
patients in everyday medical care, will be important to AFIRM."
AFIRM will be dedicated to repairing battlefield injuries through
the use of regenerative medicine, science that takes advantage of the
body's natural healing powers to restore or replace damaged tissue
and organs. In addition to developing clinical treatments, AFIRM will
serve as a training facility to develop experts in treating trauma
with regenerative medicine and will serve as a resource to help the
military develop tissues as needs are identified. Therapies developed
by AFIRM will also benefit people in the civilian population with
burns or severe trauma.
In addition to its clinical research activities, the AFIRM will
create cooperative partnerships with industry to ensure that the
technical innovations emerging from the research will transition
rapidly into militarily relevant therapies and result in producible
technologies, and ultimately will be translated into civilian
population applications as well. The AFIRM will incorporate a close
integration between basic science research and translational and
clinical research in order to bring to practice effective
regenerative medicine therapies.
The Wake Forest-University of Pittsburgh team has committed to
develop clinical therapies over the next five years that will focus
on the following five areas:
-- Burn repair
-- Wound healing without scarring
-- Craniofacial reconstruction
-- Limb reconstruction, regeneration or transplantation
-- Compartment syndrome, a condition related to inflammation
after surgery
or injury that can lead to increased pressure, impaired blood
flow,
nerve damage and muscle death
Collaborators for the Wake Forest-McGowan team include
Organogenesis,
Inc., Tufts University, Allegheny Singer Research Institute, the
California
Institute of Technology, Carnegie Mellon University, Georgia
Institute of
Technology, Intercytex, North Carolina State University, Oregon
Medical
Laser Center at Providence St. Vincent Medical Center, Pittsburgh
Tissue
Engineering Initiative, Rice University, the Stanford University
School of
Medicine, the University of California, Santa Barbara, the University
of
North Carolina, the University of Texas Health Science Center at
Houston,
the University of Wisconsin, and Vanderbilt University.
More than 50 technologies from the AFIRM team already have had a
wide
impact on treatments for illness and injury. Researchers have
launched more
than 10 clinical trials (three with the Army) using tissue engineered
products that have now been implanted in more than 1 million patients.
For instance, Organogenesis is the first company to successfully
mass
produce living regenerative medicine products -- reaching hundreds of
thousands of patients in the U.S. and other markets across the world.
Its
signature product, Apligraf(R), is the first bio-engineered living
cell
therapy to have received FDA approvals to close diabetic foot ulcers
and
venous leg ulcers.
Government sponsors of AFIRM are the U.S. Army Medical Research
and
Materiel Command, the Office of Naval Research, the U.S. Air Force
Office
of the Surgeon General, the Department of Veterans Affairs and the
National
Institutes of Health. In addition to this funding, Wake Forest and its
partners will provide more than $150 million from academic
institutions,
industry and state and federal agencies for the projects -- for a
total of
almost $200 million available for soldier regeneration research.
About Regenerative Medicine
A new frontier in healthcare, regenerative medicine utilizes
living
human cells, including stem cells, to repair or replace body tissue
damaged
by injury, disease or even the natural aging process.
Regenerative medicine is a multidisciplinary field which brings
together biology, medicine, and engineering to empower scientists to
grow
living cells, tissues and organs in the laboratory, and to safely
implant
them into the human body for the purposes of healing.
About Organogenesis, Inc.
Massachusetts based Organogenesis, Inc. is the world's most
successful
regenerative medicine company and is focused in areas of bio-active
wound
healing, bio-surgery and bio-aesthetics. Organogenesis delivers living
tissue "on demand," and its mission is to bring the medical marvel of
regenerative medicine products to patients and to standardize their
use in
everyday medical care.
Organogenesis is in the midst of a large expansion, both in the
U.S.,
as well as overseas. As the world's leading Regenerative Medicine
company,
Organogenesis has broadened its international scope and ties over the
past
few years. The company has recently established European headquarters
located in Switzerland. In addition, last December the company
announced an
agreement with China's National Tissue Engineering Center (NTEC), a
leading
stem cell and regenerative medicine consortium, headquartered in
Shanghai,
for the commercialization of Organogenesis, Inc. technology within the
Chinese market, and potentially throughout Asia. For more information,
visit http://www.organoge
SOURCE Organogenesis, Inc.
http://www.prnewswi
ACCT=104&STORY=
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
No comments:
Post a Comment